The Mercy Health - Cincinnati Cancer and Cellular Therapy Center at The Jewish Hospital is the Tri-state region’s most established blood cancer center. It recently earned recertification and the Gold Seal of Approval® from the Joint Commission for its bone marrow transplant program. The Gold Seal of Approval® is a symbol of quality that reflects an organization’s commitment to providing safe and effective patient care.
The Cincinnati Cancer and Cellular Therapy Center is one of only two bone marrow transplant programs in the United States to hold this certification.
Now in its 32nd year of operation, the Cincinnati Cancer and Cellular Therapy Center underwent a virtual survey and intense review of its bone marrow transplant program to earn recertification. The recertification review evaluates how organizations use clinical outcomes and performance measures to identify opportunities to improve care, as well as to educate and prepare patients and their caregivers for discharge.
“It’s heartening to see the close relationships that grow between patients, their families and the Cincinnati Cancer and Cellular Therapy Center team. Blood cancers take time to treat and when you come to us for care, you become part of our family,” said The Jewish Hospital President Pat Davis-Hagens. “Seeing our patients get well and go back to doing what they love is a tremendous source of joy. Third party-validation of the quality of our work from the Joint Commission, the premier health care quality improvement and accrediting body in the nation, is an honor we are proud to share among our team.”
“Bone Marrow Transplant Recertification recognizes health care organizations committed to fostering continuous quality improvement in patient safety and quality of care,” says Mark Pelletier, RN, MS, chief operating officer, Accreditation and Certification Operations, and chief nursing executive, The Joint Commission. “We commend the Mercy Health - Cincinnati Cancer and Cellular Therapy Center at The Jewish Hospital for using certification to reduce variation in its clinical processes and to strengthen its program structure and management framework for blood cancer patients.”
The Cincinnati Cancer and Cellular Therapy Center bone marrow transplant program provides outcomes comparable to those of top cancer centers regionally and nationally in overall survival of adult blood cancer and marrow transplant patients. Earlier this year, the center was the first in the region to treat a multiple myeloma patient with Chimeric Antigen Receptor (CAR) T-Cell Therapy, also known as CAR-T.
Each year, thousands of people develop blood diseases, such as leukemia, Hodgkin’s disease, non-Hodgkin’s lymphoma and multiple myeloma that are treatable with blood stem cell or bone marrow transplants. The Cincinnati Cancer and Cellular Therapy Center has been performing bone marrow transplants since 1993. Currently, it performs more than 100 blood and bone marrow transplants each year.